Objectives: Persistent disease activity is associated with a poor prognosis in inflammatory
bowel disease (IBD). Therefore, monitoring of patients with intent to suppress subclinical …

More than one-fifth of the world's population live in extreme poverty, where a lack of safe
water and adequate sanitation enables high rates of enteric infections and diarrhoea to …

Currently, the main targets of drug therapy for ulcerative colitis [UC] are endoscopic and
clinical remission. However, there is active discussion about the additional advantages of …

Fecal and serologic biomarkers can be used in the diagnosis and management of
inflammatory bowel disease (IBD). Fecal markers such as calprotectin and lactoferrin have …

Inflammatory bowel disease (IBD) is characterized as chronic inflammation in the
gastrointestinal tract, which includes two main subtypes, Crohn's disease and ulcerative …

Promising therapy is needed for treating inflammatory bowel diseases (IBD) to overcome
current treatment that inefficient and associated with unnecessary health risks. Recently, the …

Crohn's disease and ulcerative colitis are characterized by periods of symptomatic relapse
and remission. Diagnosis and assessment of inflammatory bowel disease has so far been …

Hypochlorous acid (HOCl) is produced in the human body by the family of mammalian heme
peroxidases, mainly by myeloperoxidase, which is secreted by neutrophils and monocytes …

Background As a chronic inflammatory disease, ulcerative colitis (UC) is relevant to a rising
risk of colorectal cancer. Dihydroberberine (DHBB), a natural occurring isoquinoline alkaloid …

Differentiating patients with inflammatory disease from those with functional disorders may
be difficult in patients with nonspecific symptoms, such as diarrhea and abdominal pain …